Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

Not everyone in the health field is so bullish on the prospects of CGMs for everyone, and question whether digging in too ...

Continuous Glucose Monitoring Devices Market to reach a value of US$ 12.51 Bn by 2031 at a CAGR of 9.9% between 2024 and 2031 BURLINGAME, CA, UNITED STATES, October 15, 2024 /EINPresswire / -- A ...

In recent years, digital health has become a new development trend in the global health and medical industry. By using ...

Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...

Normoglycemic individuals spent 87% of their daily time in in the “tight range” of glucose levels (70-140 mg/dL) and the remainder above 140 mg/dL.

DexCom, Inc. (NASDAQ:DXCM) has also consistently beat EPS estimates in the last 4 quarters. The stock has received an average ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

More and more people are talking abut the monitoring device, also known as CGM, for non-diabetics. But not everyone in the health field is so bullish on the prospects of CGMs for everyone ...